Company Overview - Dongpeng Beverage (605499) has submitted an application to the Hong Kong Stock Exchange, with Huatai International, Morgan Stanley, and UBS Group as joint sponsors [1] - As the leading functional beverage company in China, Dongpeng Beverage ranks first in revenue growth among the top 20 listed soft drink companies globally [1] - The company has over 30 years of industry experience and has successfully built the "Dongpeng" national brand while continuously innovating products and expanding categories [1] Market Position - According to a Frost & Sullivan report, Dongpeng Beverage has ranked first in sales volume in China's functional beverage market for four consecutive years since 2021, with a significant increase in market share [1] - By retail value, Dongpeng Beverage is projected to be the second-largest functional beverage company in China in 2024, holding a market share of 23.0% [1] Sales Network and Digital Operations - As of June 30, 2025, Dongpeng Beverage has established a comprehensive sales network covering over 4.2 million terminal sales points nationwide [1] - The company employs refined channel management and a "product + service" model, being a pioneer in utilizing "one code for one product" and "five codes association" technology for product traceability [1] - Its integrated digital operation system connects over 250 million consumers, 4.2 million terminal sales points, and 3,200 distribution partners [1] Industry Insights - The retail value of China's soft drink industry is approximately RMB 1.3 trillion in 2024, making it the second-largest consumer market globally [2] - Functional beverages are the fastest-growing segment, with a compound annual growth rate (CAGR) of 8.3% from 2019 to 2024, surpassing the overall soft drink market growth of 4.7% during the same period [2] - It is expected that the retail value of China's energy drink industry will reach RMB 180.7 billion by 2029, with a CAGR of 10.3% from 2025 to 2029 [2]

Core Viewpoint - Binhui Biotech has submitted a listing application to the Hong Kong Stock Exchange, with Huatai International, CMB International, and Bank of China International as joint sponsors [1] Company Overview - Binhui Biotech is a biotechnology company focused on the discovery, development, and commercialization of cancer immunotherapy, specifically on oncolytic virus therapy [1] - The company's lead product, BS001 (OH2 injection), is an oncolytic virus candidate based on type II herpes simplex virus (HSV-2) that selectively replicates in tumor cells and activates systemic immunity [1] Product Development - BS001 is the first oncolytic virus candidate based on HSV-2 to reach clinical stage and enter Phase III pivotal trials globally, currently undergoing a Phase III clinical trial for melanoma in China [1] - BS001 has received orphan drug designation from the FDA for the treatment of stage III-IV melanoma and malignant glioma, as well as fast track designation for treating refractory or progressive melanoma [1] - In a Phase Ia/Ib trial, BS001 demonstrated a median overall survival of 31.06 months, with an objective response rate of 34.48%, and up to 42.1% in patients resistant to PD-1 therapy [1] Leadership and Expertise - The company is led by Dr. Liu Binlei, who has over 30 years of experience in tumor immunology and oncolytic virology, and was a core member of the development team for the FDA-approved oncolytic virus drug IMLYGIC® (T-VEC) [1]

每经AI快讯，9月30日，港交所文件显示，安徽华恒生物科技股份有限公司向港交所提交上市申请书， 独家保荐人为华泰国际。 ...

Core Viewpoint - Lio Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with Huatai International and China Galaxy International as sponsors [1] Group 1: Business Overview - Lio Co., Ltd. operates with a dual core business model of AI-driven digital marketing and smart pumps and systems, creating unique industrial barriers through complementary advantages [1] - In the smart pumps and systems sector, the company ranks second in China and thirteenth globally, establishing itself as the leading provider in the domestic civil pump export market [1] - The company's products are distributed across over 160 countries and regions [1]

Core Viewpoint - Liou Co., Ltd. has submitted an application to the Hong Kong Stock Exchange, focusing on "AI-driven digital marketing and smart pumps and systems" as its core business model, which creates a unique industrial barrier and supports stable development [1] Group 1: Business Overview - Liou Co., Ltd. operates with a dual-core business model of "AI digital marketing + smart pumps and systems," which allows for complementary advantages and collaborative empowerment [1] - The AI digital marketing segment is projected to achieve the largest revenue scale in China's digital marketing market by 2024, holding a market share of 8.72% in the digital advertising agency sector, ranking first in the industry [1] - The smart pumps and systems segment ranks second in China's pump and system industry and thirteenth globally by revenue in 2024, with the highest export value in the domestic civil pump sector [1] Group 2: Financial Performance - Total revenue for 2022, 2023, and 2024 is projected to be 20.268 billion, 20.471 billion, and 21.171 billion respectively, indicating stable growth [2] - The gross profit margin is expected to remain in the range of 8.4% to 8.9%, reflecting stable profitability [2] - As of June 30, 2025, the current ratio is projected to be 2.3, and the debt-to-asset ratio is 14.2%, indicating a healthy financial structure and strong risk resistance [2] Group 3: Cash Flow Management - The cash flow contribution from the two core businesses is stable, with the pump and system business achieving a cash flow recovery rate exceeding 90% due to a "payment before delivery" settlement model [2] - The digital marketing business effectively controls accounts receivable turnover days, projected to be 93 days in 2024, showcasing outstanding overall working capital management [2]

Group 1 - The company, LEO Group Co., Ltd., has submitted a listing application to the Hong Kong Stock Exchange [1] - The joint sponsors for the listing are Huatai International and China Galaxy International [1]

大金重工股份有限公司向港交所提交上市申请书，联席保荐人为华泰国际、招商证券国际。 ...

每经AI快讯，据港交所9月28日披露，圣邦微电子(北京)股份有限公司(简称：圣邦微电子)向港交所主板 提交上市申请书，华泰国际、中金公司为其联席保荐人。 ...

Group 1 - The China Securities Regulatory Commission (CSRC) issued supplementary material requirements for five companies, including Wolong Electric Drive, regarding their overseas listing applications [1] - Wolong Electric Drive is required to clarify inconsistencies in the identification of its controlling shareholder and provide a conclusive legal opinion on this matter [1] - The company must disclose specific details about the pledged shares of its controlling shareholder and assess the impact on its control and normal business operations [1] Group 2 - Wolong Electric Drive is a provider of electric drive system solutions, focusing on the research, production, sales, and service of electric drive system products [2] - The company ranks first in the global explosion-proof electric drive system solutions market with a market share of approximately 4.5%, fourth in the global industrial electric drive system solutions market with a market share of about 2.8%, and fifth in the global HVAC electric drive system solutions market with a market share of around 2.0% [2]

智通财经获悉，9月25日，全球领先的乘用车公司奇瑞汽车股份有限公司（以下简称"奇瑞汽车"、"公 司"，股票代码为9973.HK）成功于香港联交所主板挂牌上市。此次奇瑞汽车全球发售以每股30.75港元 高端定价，发行总规模约为11.74亿美元（绿鞋前），本次发行另设置15%超额配股权，为2023年以来 规模最大的首发H股IPO，同时为2025年规模最大的整车企业港股IPO。本次发行的国际配售部分获得 11.61倍认购，香港公开发售部分获得308.18倍认购。华泰国际于本次发行中担任联席保荐人、保荐人兼 整体协调人、整体协调人、联席全球协调人、联席账簿管理人及联席牵头经办人。 奇瑞汽车致力于成为创新驱动、全球信赖的智能出行生态引领者。本次上市是奇瑞汽车融入国际资本市 场的重要举措，通过国际资本市场平台赋能，公司将进一步打造全球化品牌形象、深化国际化战略布 局，并加速其战略目标的实现，同时也让中国优质企业进一步走进国际投资者的视野。 奇瑞汽车作为一家全球化的乘用车公司，通过设计、开发、制造和销售多样化且不断扩展的乘用车产品 组合，能够持续满足国内外市场用户的多样性需求。公司2024年营业收入2,698.97亿元，同 ...